Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Key Inclusion Criteria:

• Histopathologic confirmation of one of the following cluster of differentiationantigen 20 positive (CD20+) B-cell non-Hodgkin's lymphomas (tissue diagnosticprocedures must be performed within 6 months of study entry and with biopsy materialavailable for review):

• follicular lymphoma (NCI CTCAE grade 1 or 2)

• immunoplasmacytoma/immunocytoma (Waldenstrom's macroglobulinemia)

• splenic marginal zone B-cell lymphoma

• extra-nodal marginal zone lymphoma of mucosa-associated lymphoid tumor (MALT)type

• nodal marginal zone B-cell lymphoma

• mantle cell lymphoma

• Meets one of the following need-for-treatment criteria (with the exception of mantlecell lymphoma for which treatment is indicated):

• presence of at least one of the following B-symptoms:

1. fever (>38ºC) of unclear etiology

2. night sweats

3. weight loss of greater than 10% within the prior 6 months

• large tumor mass (bulky disease)

• presence of lymphoma-related complications, including narrowing of ureters orbile ducts, tumor-related compression of a vital organ, lymphoma-induced pain,cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, orascites

• hyperviscosity syndrome due to monoclonal gammopathy

• CD20+ B cells in lymph node biopsy or other lymphoma pathology specimen.

• No prior treatment (patients on "watch and wait" may enter the study if a recentbiopsy [obtained within the last 6 months] is available)

• Adequate hematologic function (unless abnormalities related to lymphoma infiltrationof the bone marrow or hypersplenism due to lymphoma) as follows:

• hemoglobin of >= 10.0 g/dL

• absolute neutrophil count (ANC) >=1.5*10^9/L

• platelet count >=100*10^9/L

• Bidimensionally measurable disease (field not previously radiated)

• Able to provide written informed consent

• Eastern Cooperative Oncology Group (ECOG) Performance Status <=2

• Estimated life expectancy >=6 months

• Serum creatinine of <=2.0 mg/dL or creatinine clearance >=50 mL/min

• Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5*upper limit ofnormal (ULN), and alkaline phosphatase and total bilirubin within normal limits

• Left ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated withR-CHOP

• A medically accepted method of contraception to be used by women of childbearingpotential (not surgically sterile or at least 12 months naturally postmenopausal)

• Men capable of producing offspring and not surgically sterile must practice abstinenceor use a barrier method of birth control.

Key Exclusion Criteria:

• Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade 3 follicularlymphoma

• Transformed disease (bone marrow blasts are permitted; however, transformed diseaseindicating leukemic involvement is not permitted)

• Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma

• Prior radiation for NHL, except for a single course of locally delimited radiationtherapy with a radiation field not exceeding 2 adjacent lymph node regions

• Active malignancy, other than NHL, within the past 3 years except for localizedprostate cancer treated with hormone therapy, cervical carcinoma in situ, breastcancer in situ, or non-melanoma skin cancer following definitive treatment

• New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias orunstable angina, electrocardiograph (ECG) evidence of active ischemia or activeconduction system abnormalities, or myocardial infarction within the last 6 months (prior to study entry, ECG abnormalities at screening must be documented by theinvestigator as not medically relevant)

• Known human immunodeficiency virus (HIV) positivity

• Active hepatitis B or hepatitis C infection (hepatitis B surface antigen testingrequired)

• Women who are pregnant or lactating

• Corticosteroids for treatment of lymphoma within 28 days of study entry Chronicallyadministered low-dose corticosteroids (e.g., prednisone ≤20 mg/day) for indicationsother than lymphoma or lymphoma-related complications are permitted

• Any serious uncontrolled, medical or psychological disorder that would impair theability of the patient to receive therapy

• Any condition which places the patient at unacceptable risk or confounds the abilityof the investigators to interpret study data

• Any other investigational agent within 28 days of study entry

• Known hypersensitivity to bendamustine, mannitol, or other study-related drugs

• Ann Arbor stage I disease.